| Date Filed | Type | Description |
| 02/14/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 09/09/2016 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)] |
| 09/06/2016 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 09/02/2016 |
SC 13G/A
| Vivo Ventures V, LLC reports a 0% stake in Sagent Pharmaceuticals, Inc. |
| 09/01/2016 |
4
| Vivo Ventures V, LLC (10% Owner) has filed a Form 4 on Sagent Pharmaceuticals, Inc. |
| 09/01/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 08/31/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 08/31/2016 |
4
| OBERMAN ALLAN (CEO) has filed a Form 4 on Sagent Pharmaceuticals, Inc. |
| 08/31/2016 |
4
| Krizman Anthony (Director) has filed a Form 4 on Sagent Pharmaceuticals, Inc. |
| 08/31/2016 |
4
| BULLOCK DONALD R (Executive V.P. Sales) has filed a Form 4 on Sagent Pharmaceuticals, Inc. |
| 08/31/2016 |
4
| Behrens Mary Taylor (Director) has filed a Form 4 on Sagent Pharmaceuticals, Inc.|
Txns:
| Unknown transaction of 7,097 shares
@ $21.75, valued at
$154.4k
Disposed/sold 8,556 restricted stock units
@ $21.75, valued at
$186.1k
Disposed/sold 691 restricted stock units
@ $21.75, valued at
$15k
Disposed/sold 1,381 restricted stock units
@ $21.75, valued at
$30k
Disposed/sold 1,860 restricted stock units
@ $21.75, valued at
$40.5k
Disposed/sold 760 restricted stock units
@ $21.75, valued at
$16.5k
Disposed/sold 6,379 options to buy
@ $11.6, valued at
$74k
|
|
| 08/31/2016 |
4
| FLANAGAN ROBERT J (Director) has filed a Form 4 on Sagent Pharmaceuticals, Inc.|
Txns:
| Gifted 4,150 shares
@ $0
Unknown transaction of 8,050 shares
@ $21.75, valued at
$175.1k
Unknown transaction of 2,000 shares
@ $21.75, valued at
$43.5k
Unknown transaction of 433,770 shares
@ $21.75, valued at
$9.4M
Disposed/sold 8,556 restricted stock units
@ $21.75, valued at
$186.1k
Disposed/sold 691 restricted stock units
@ $21.75, valued at
$15k
Disposed/sold 1,381 restricted stock units
@ $21.75, valued at
$30k
Disposed/sold 1,860 restricted stock units
@ $21.75, valued at
$40.5k
Disposed/sold 760 restricted stock units
@ $21.75, valued at
$16.5k
Disposed/sold 5,103 options to buy
@ $11.6, valued at
$59.2k
|
|
| 08/31/2016 |
4
| BRYNJELSEN SEAN (EVP, Business Development) has filed a Form 4 on Sagent Pharmaceuticals, Inc. |
| 08/31/2016 |
4
| WARD MICHAEL V. (Chief Legal Off. and Secretary) has filed a Form 4 on Sagent Pharmaceuticals, Inc. |
| 08/31/2016 |
4
| FEKETE MICHAEL (Director) has filed a Form 4 on Sagent Pharmaceuticals, Inc. |
| 08/31/2016 |
4
| Harmon J Frank (EVP, Global Operations) has filed a Form 4 on Sagent Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 8,915 shares
@ $21.75, valued at
$193.9k
Disposed/sold 18,897 options to buy
@ $13.46, valued at
$254.4k
|
|
| 08/31/2016 |
4
| Greve Jeffrey W. (Vice President, Controller) has filed a Form 4 on Sagent Pharmaceuticals, Inc. |
| 08/31/2016 |
4
| Yanai Shlomo (Director) has filed a Form 4 on Sagent Pharmaceuticals, Inc. |
| 08/30/2016 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 08/30/2016 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement |
| 08/29/2016 |
8-K
| Quarterly results |
| 08/29/2016 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities |
| 08/29/2016 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party [Amend] |
| 08/24/2016 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party [Amend] |
| 08/22/2016 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party [Amend] |
| 08/18/2016 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party [Amend] |
| 08/09/2016 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party [Amend] |
| 08/05/2016 |
4
| OBERMAN ALLAN (CEO) has filed a Form 4 on Sagent Pharmaceuticals, Inc. |
| 08/05/2016 |
10-Q
| Quarterly Report for the period ended June 30, 2016 |
| 08/02/2016 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party [Amend] |
| 08/01/2016 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements |
| 08/01/2016 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party |
| 07/13/2016 |
4
| FEKETE MICHAEL (Director) has filed a Form 4 on Sagent Pharmaceuticals, Inc.|
Txns:
| Exercised 591 restricted stock units
@ $0 |
|
| 07/12/2016 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer |
|